Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
16.31
-0.57 (-3.38%)
At close: Apr 28, 2026, 4:00 PM EDT
16.40
+0.09 (0.55%)
After-hours: Apr 28, 2026, 7:06 PM EDT
Amylyx Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Amylyx Pharmaceuticals stock have an average target of 21.56, with a low estimate of 10 and a high estimate of 34. The average target predicts an increase of 32.19% from the current stock price of 16.31.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Amylyx Pharmaceuticals stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 6 | 6 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $19 → $21 | Buy | Maintains | $19 → $21 | +28.76% | Apr 28, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $34 | Strong Buy | Reiterates | $34 | +108.46% | Mar 25, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $25 → $30 | Strong Buy | Maintains | $25 → $30 | +83.94% | Mar 19, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $28 → $34 | Strong Buy | Maintains | $28 → $34 | +108.46% | Mar 4, 2026 |
| Stifel | Stifel | Strong Buy Initiates $21 | Strong Buy | Initiates | $21 | +28.76% | Mar 3, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
45.58M
EPS This Year
-1.41
from -1.53
EPS Next Year
-1.38
from -1.41
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 132.0M | ||||||
| Avg | n/a | 45.6M | ||||||
| Low | n/a | 2.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.90 | -0.40 | ||||||
| Avg | -1.41 | -1.38 | ||||||
| Low | -1.59 | -1.71 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.